Beyond MS: How to Spot Rare Demyelinating Disorders That Mimic Multiple Sclerosis
A comprehensive review details how NMOSD, MOGAD, and other rare CNS disorders are frequently mistaken for MS — and how to tell them apart.
Summary
Multiple sclerosis is not the only disease that damages the brain's myelin sheath. This review highlights a spectrum of rarer conditions — including neuromyelitis optica spectrum disorder (NMOSD), MOG antibody disease (MOGAD), and unusual mimics like Behcet disease and Susac syndrome — that can look nearly identical to MS on MRI and in clinical presentation. Crucially, these conditions require different treatments, so misdiagnosis carries real consequences. The review also covers updated 2024 McDonald diagnostic criteria for MS, which now incorporate new MRI biomarkers like the central vein sign and paramagnetic ring lesions, plus a new CSF biomarker. For clinicians and engaged patients alike, understanding these distinctions is essential for timely, accurate diagnosis and appropriate management of serious neurological disease.
Detailed Summary
Accurate diagnosis of multiple sclerosis is critically dependent on ruling out a broad array of other central nervous system disorders that share overlapping clinical, radiological, and pathological features. Misclassification leads to patients receiving treatments that are not only ineffective but potentially harmful — making this review directly relevant to neurologists and other clinicians managing demyelinating disease.
The review, published in Current Neurology and Neuroscience Reports, surveys uncommon non-MS demyelinating and demyelination-mimicking conditions, with particular emphasis on neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody disease (MOGAD). NMOSD is driven by antibodies targeting aquaporin-4, a water channel protein on astrocytic foot processes, while MOGAD involves antibodies against myelin oligodendrocyte glycoprotein. Both preferentially attack the optic nerves and spinal cord, producing relapsing optic neuritis and transverse myelitis that can cause blindness and paralysis. Importantly, about 42% of AQP4-seronegative NMOSD patients test positive for MOG antibodies, establishing MOGAD as a distinct entity frequently miscategorized as MS or NMOSD.
Key diagnostic advances are highlighted, including the revised 2024 McDonald criteria from ECTRIMS, which now incorporate three new features: the central vein sign (a blood vessel visible at the center of MS lesions on MRI), paramagnetic ring lesions (iron rings surrounding active plaques), and CSF kappa free light chains as a biomarker equivalent to oligoclonal bands. These additions sharpen MS-specific diagnosis and help exclude mimics.
The review also covers rarer mimics including antiphospholipid syndrome, CLIPPERS, Susac syndrome, leukodystrophies, CNS lymphoma, COVID-19-related white matter changes, and vascular conditions like CADASIL. Genetic testing advances, including whole exome sequencing, are reclassifying some apparent atypical MS cases as leukodystrophies.
The primary caveat is that this summary is based on the abstract alone, limiting granularity on specific diagnostic algorithms and management protocols. The review is narrative rather than systematic, which may introduce selection bias in the conditions emphasized.
Key Findings
- MOGAD accounts for ~42% of AQP4-seronegative NMOSD cases and is now recognized as a distinct treatable condition.
- 2024 McDonald MS criteria add central vein sign, paramagnetic ring lesions, and CSF kappa free light chains as new diagnostic markers.
- NMOSD causes blindness and paralysis in 60–80% of cases via optic neuritis and longitudinally extensive transverse myelitis.
- Rare mimics like Susac syndrome, CLIPPERS, and CADASIL are frequently misdiagnosed as MS, delaying appropriate therapy.
- Whole exome sequencing is reclassifying some atypical MS diagnoses as leukodystrophies, changing management entirely.
Methodology
This is a narrative review article published in a peer-reviewed neurology journal, synthesizing recent literature on non-MS demyelinating CNS disorders. The authors draw on clinical, radiological, and serological evidence to distinguish these conditions from MS. No formal systematic review or meta-analysis methodology is described.
Study Limitations
This summary is based on the abstract only, as the full text is not open access, limiting detail on specific diagnostic algorithms and treatment recommendations. The review is narrative rather than systematic, which may introduce selection bias regarding which conditions receive emphasis. Evidence quality for rarer mimics discussed may vary considerably.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.